Profile data is unavailable for this security.
About the company
BSF Enterprise PLC is a United Kingdom-based biotechnology company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBT’s City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBT’s Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.
- Revenue in GBP (TTM)12.94k
- Net income in GBP-1.50m
- Incorporated2018
- Employees4.00
- LocationBSF Enterprise PLCGround Floor, 31 Old Burlington StreetLONDON W1S 3ASUnited KingdomGBR
- Phone+44 203 283 4590
- Websitehttps://bsfenterprise.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 1.47m | 7.00 | -- | 0.6649 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| Nuformix PLC | 0.00 | -436.95k | 1.52m | 2.00 | -- | 0.3282 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| N4 Pharma PLC | 1.95k | -1.28m | 2.15m | 5.00 | -- | 1.91 | -- | 1,102.69 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 2.39m | 25.00 | -- | 2.78 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| TheraCryf PLC | 838.00k | -3.35m | 3.21m | 7.00 | -- | 0.5239 | -- | 3.82 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.29m | 50.00 | -- | 1.41 | -- | 2.08 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| IXICO PLC | 6.67m | -1.18m | 3.57m | 89.00 | -- | 0.3119 | -- | 0.535 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 4.91m | 4.00 | -- | 1.01 | -- | 379.33 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| ValiRx Plc | 9.60k | -2.04m | 5.29m | 8.00 | -- | 1.27 | -- | 551.45 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 6.64m | 67.00 | -- | 4.04 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
